The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. Through this notice, FDA is hoping to stimulate the economy and increase the regulatory certainty with respect to generic versions of these drug products by confirming that generic versions of the subject drug products may continue to be marketed.
Document
Determination That DEMEROL (Meperidine Hydrochloride) Injectable and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA or Agency) has determined that the drug products listed in this document were not withdrawn from sale for reasons of safety or effectivenes...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 19735
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Determination That DEMEROL (Meperidine Hydrochloride) Injectable and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” thefederalregister.org (April 28, 2017), https://thefederalregister.org/documents/2017-08582/determination-that-demerol-meperidine-hydrochloride-injectable-and-other-drug-products-were-not-withdrawn-from-sale-for-.